Latest news with #JimSimons
Yahoo
14-05-2025
- Business
- Yahoo
Renaissance Technologies' Strategic Moves: Apple Inc. Reduction by 0.91%
Renaissance Technologies (Trades, Portfolio) recently submitted its 13F filing for the first quarter of 2025, offering a glimpse into its strategic investment decisions during this period. Founded in 1978 by Jim Simons, Renaissance Technologies (Trades, Portfolio) LLC is a renowned private investment firm based in New York. Known for its pioneering approach in quantitative trading, the firm employs complex mathematical models to analyze and execute trades, many of which are automated. Simons, who stepped down as CEO in 2010 and retired as chairman in 2021, passed away in May 2024 at the age of 86. The firm continues to leverage computer-based models to predict price changes in easily-traded financial instruments, focusing on non-random movements to make informed predictions. Renaissance Technologies (Trades, Portfolio) added a total of 460 stocks, among them: The most significant addition was ServiceNow Inc (NYSE:NOW), with 272,301 shares, accounting for 0.33% of the portfolio and a total value of $216.79 million. The second largest addition to the portfolio was Alphabet Inc (NASDAQ:GOOG), consisting of 1,317,620 shares, representing approximately 0.31% of the portfolio, with a total value of $205.85 million. The third largest addition was American Airlines Group Inc (NASDAQ:AAL), with 17,213,832 shares, accounting for 0.27% of the portfolio and a total value of $181.61 million. Renaissance Technologies (Trades, Portfolio) also increased stakes in a total of 1,470 stocks, among them: The most notable increase was Broadcom Inc (NASDAQ:AVGO), with an additional 2,425,176 shares, bringing the total to 2,427,714 shares. This adjustment represents a significant 95,554.61% increase in share count, a 0.62% impact on the current portfolio, with a total value of $406.47 million. The second largest increase was Alphabet Inc (NASDAQ:GOOGL), with an additional 2,272,750 shares, bringing the total to 2,275,800. This adjustment represents a significant 74,516.39% increase in share count, with a total value of $351.93 million. Renaissance Technologies (Trades, Portfolio) completely exited 588 holdings in the first quarter of 2025, as detailed below: Nike Inc (NYSE:NKE): Renaissance Technologies (Trades, Portfolio) sold all 2,602,101 shares, resulting in a -0.29% impact on the portfolio. AutoZone Inc (NYSE:AZO): Renaissance Technologies (Trades, Portfolio) liquidated all 49,200 shares, causing a -0.23% impact on the portfolio. Renaissance Technologies (Trades, Portfolio) also reduced positions in 1,441 stocks. The most significant changes include: Reduced Apple Inc (NASDAQ:AAPL) by 2,463,237 shares, resulting in a -99.82% decrease in shares and a -0.91% impact on the portfolio. The stock traded at an average price of $231.67 during the quarter and has returned -13.08% over the past 3 months and -15.01% year-to-date. Reduced Palantir Technologies Inc (NASDAQ:PLTR) by 6,499,936 shares, resulting in a -28.52% reduction in shares and a -0.73% impact on the portfolio. The stock traded at an average price of $87.82 during the quarter and has returned 9.25% over the past 3 months and 72.13% year-to-date. At the first quarter of 2025, Renaissance Technologies (Trades, Portfolio)' portfolio included 3,407 stocks. The top holdings included 2.08% in Palantir Technologies Inc (NASDAQ:PLTR), 1.16% in VeriSign Inc (NASDAQ:VRSN), 1.06% in Corcept Therapeutics Inc (NASDAQ:CORT), 1.05% in Robinhood Markets Inc (NASDAQ:HOOD), and 0.99% in Sprouts Farmers Market Inc (NASDAQ:SFM). The holdings are mainly concentrated in all 11 industries: Technology, Healthcare, Consumer Cyclical, Financial Services, Industrials, Communication Services, Consumer Defensive, Basic Materials, Energy, Real Estate, and Utilities. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Business
- Yahoo
Is Palantir Technologies (PLTR) the Best Stock to Buy According to Jim Simons' Renaissance Technologies?
We recently published a list of In this article, we are going to take a look at where Palantir Technologies Inc. (NASDAQ:PLTR) stands against other best stocks to buy according to Jim Simons' Renaissance Technologies. Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the 'Quant King' of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative trading firm based in New York. After years of researching the finance industry, Simons realized the untapped potential of employing quantitative analysis to capitalize on market inefficiencies. This insight led him to develop a data-driven investment strategy of analyzing market behavior solely using statistical and mathematical models. By identifying subtle, non-random patterns in financial data, the quant genius predicted future stock movements and generated impressive returns. Although it is closed to outside investors, Jim Simons' secretive Medallion hedge fund, a flagship of Renaissance, has produced ground-breaking results since its inception. The Medallion Fund raked in impressive returns of 56.6% and 74.6% during the early 2000s dot-com crash and the global financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $31.4 billion, ranking him among the world's wealthiest individuals, thanks to the strong market performance of the Medallion Fund and Renaissance. READ ALSO: and . Renaissance Technologies' computer-driven powerhouse came off to a great start after a stellar performance in 2024. The Renaissance Institutional Diversified Alpha Fund has gained 9.05% as of February, continuing to build on its impressive 2024 return of 15.6%, which was its best since its inception in 2021. Meanwhile, the Renaissance Institutional Equities Fund has had its best start in over ten years, rising 11.85% in the first two months of 2025. Both funds are allowed to maintain sizable individual stock positions in addition to using stock index futures and options to help manage risk. However, the firm warns that it may be difficult to quickly unwind these sizable holdings without impacting market prices. For this list, we picked stocks from Renaissance Technologies' 13F portfolio as of the end of the fourth quarter of 2024. These equities are also popular among elite hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A software engineer manipulating a vast network of code on virtual monitors. Palantir Technologies Inc. (NASDAQ:PLTR) is a software and data analytics company that develops platforms for large corporations, financial institutions, and government organizations to analyze massive amounts of data. Its government sector serves customers from the US government and non-US government agencies, while the commercial segment oversees clients from various non-governmental industries. On May 6, Cantor Fitzgerald raised its price target for Palantir Technologies Inc. (NASDAQ:PLTR) from $98 to $110 with a Neutral rating on the stock. This change follows Palantir's first-quarter 2025 earnings, which beat the Visible Alpha consensus by 2.5%. The company attributed this outperformance to strong results in the U.S. commercial sector, where revenue surpassed projections by 10%, and overall government revenue, which was 5% higher than anticipated. However, Cantor Fitzgerald observed that the degree of revenue outperformance was lower compared to the prior quarter, despite the report's positive aspects. Due to persistent challenges across Europe, international revenues, especially among the commercial sectors abroad, fell 16% short of projections. Ithaka US Growth Strategy stated the following regarding Palantir Technologies Inc. (NASDAQ:PLTR) in its Q1 2025 : 'From the front-lines of warzones to Fortune 500 enterprises, Palantir Technologies Inc. (NASDAQ:PLTR) builds software to address high-level action items, respond to defense and security concerns, and improve organizational efficiency. The company offers a number of software products from data analysis and curation (Palantir Gotham and Foundry) to a cloud-based operations software (Apollo). The company rose to popularity, in part, due to several government contracts (~55% of revenues) arising from recent and continuous global conflicts. In addition to creating generative AI defense solutions for governments across the globe, commercial customers (~45% of revenues) have flocked to the company's security and data analysis solutions to monitor and analyze business data and protect sensitive information. The stock's rise in the quarter was due to a strong earnings report that beat Street expectations as well as investor excitement with regard to the company's ability to further monetize its AI product across its growing customer base.' Overall, PLTR ranks 1st on our list of best stocks to buy according to Jim Simons' Renaissance Technologies. While we acknowledge the potential for PLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PLTR but trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
Yahoo
11-05-2025
- Business
- Yahoo
Is Airbnb (ABNB) Among the Best Stocks to Buy According to Jim Simons' Renaissance Technologies?
We recently published a list of In this article, we are going to take a look at where Airbnb, Inc. (NASDAQ:ABNB) stands against other best stocks to buy according to Jim Simons' Renaissance Technologies. Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the 'Quant King' of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative trading firm based in New York. After years of researching the finance industry, Simons realized the untapped potential of employing quantitative analysis to capitalize on market inefficiencies. This insight led him to develop a data-driven investment strategy of analyzing market behavior solely using statistical and mathematical models. By identifying subtle, non-random patterns in financial data, the quant genius predicted future stock movements and generated impressive returns. Although it is closed to outside investors, Jim Simons' secretive Medallion hedge fund, a flagship of Renaissance, has produced ground-breaking results since its inception. The Medallion Fund raked in impressive returns of 56.6% and 74.6% during the early 2000s dot-com crash and the global financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $31.4 billion, ranking him among the world's wealthiest individuals, thanks to the strong market performance of the Medallion Fund and Renaissance. READ ALSO: and . Renaissance Technologies' computer-driven powerhouse came off to a great start after a stellar performance in 2024. The Renaissance Institutional Diversified Alpha Fund has gained 9.05% as of February, continuing to build on its impressive 2024 return of 15.6%, which was its best since its inception in 2021. Meanwhile, the Renaissance Institutional Equities Fund has had its best start in over ten years, rising 11.85% in the first two months of 2025. Both funds are allowed to maintain sizable individual stock positions in addition to using stock index futures and options to help manage risk. However, the firm warns that it may be difficult to quickly unwind these sizable holdings without impacting market prices. For this list, we picked stocks from Renaissance Technologies' 13F portfolio as of the end of the fourth quarter of 2024. These equities are also popular among elite hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A vacation home luxury bedroom setup with stunning decor showing a desired getaway experience. San Francisco-based Airbnb, Inc. (NASDAQ:ABNB) runs an online marketplace that links homeowners with travelers seeking accommodation. DA Davidson reiterated its Buy rating and $155 price target for Airbnb, Inc. (NASDAQ:ABNB) on May 5. The company's analyst, Tom White, maintained his evaluation after examining Airbnb's 2025 first-quarter results. Although the company's foreign exchange-neutral gross bookings and revenue growth aligned with projections, adjusted EBITDA exceeded them, despite unit growth being marginally below forecasts. Although there was some observed softness in the U.S. market, where North America accounted for 45% of Airbnb's 2024 revenue, the analyst pointed out that the situation appeared to be more related to customers delaying decisions on longer-lead-time trips than a shift towards lower-priced options. Moreover, the company plans to relaunch its Experiences platform and add traditional hotel inventory, which may impact its development. Airbnb's management remains confident in its strategic positioning and long-term EBITDA margin guidance of 34.5% by FY25. Oakmark Global Fund stated the following regarding Airbnb, Inc. (NASDAQ:ABNB) in its : 'Airbnb, Inc. (NASDAQ:ABNB) is an online marketplace to list, discover and book unique accommodations worldwide. The company benefits from a strong network effect between its guests and hosts. We believe there is a long growth runway as global travel is an attractive market, and alternative accommodations have been taking share. We anticipate Airbnb will drive further growth by creating more valuable services for both sides of its network. This includes the potential for paid placement, which has created significant economic value for comparable market places. In our view, management is aligned with shareholders and well qualified to lead Airbnb as the company attempts to capture these growth opportunities. Short-term concerns about the macro travel environment and declining margins stemming from growth investments allowed us to purchase shares at a discount to our estimate of business value.' Overall, ABNB ranks 8th on our list of best stocks to buy according to Jim Simons' Renaissance Technologies. While we acknowledge the potential for ABNB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ABNB but trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
11-05-2025
- Business
- Globe and Mail
The Top 3 Stock Picks at the World's Greatest Hedge Fund
A reclusive firm is often considered the world's most successful hedge fund. That company is Renaissance Technologies. This company's prominence is largely due to its Medallion Fund, which generated an annualized return of 39% after fees from 1988 to 2021. Its founder, Jim Simons, became known as one of the pioneers of quantitative and algorithmic trading. Simons unfortunately passed away in May 2024, but Renaissance lives on. By looking at the company's 13F Securities and Exchange Commission (SEC) filing, anyone can see the company's top long equity holdings. However, the list of stock holdings has a 45-day lag, and the SEC does not necessarily review the holdings for accuracy. All this is to say that investors should take 13F filings with a grain of salt. Still, looking at this information can provide valuable insight into what investments one of the world's most renowned money managers has felt very strongly about. Novo Nordisk: Could Renaissance Pick Up More Shares in this Long-Time Holding? [content-module:CompanyOverview|NYSE:NVO] At the end of 2024, Renaissance's third-largest long equity holding was the pharmaceutical company, Novo Nordisk A/S (NYSE: NVO). It was the firm's second-largest equity holding in Q4 2013, and has remained at or near the top of the list almost every quarter since. The company really burst onto the scene after 2017 with its breakthrough weight loss and diabetes drug semaglutide. Novo generated a total return of around 480% from the end of 2017 to its peak in June 2024. However, since then, shares are down by a massive 56% as of the April 29 close. From Q2 2024 to Q4 2024, Renaissance reduced its holdings of Novo, but not by a massive amount. Its number of shares held fell by around 9%. Now, Novo shares are trading at the same level they were back at the end of 2022. At the end of 2024, Renaissance still had a stake in Novo of $715 million, indicating that it had strong conviction in this name at the time. Given the stock's extensive decline in 2025, it is possible Renaissance's next 13F could reveal that it upped its stake. United Therapeutics: Renaissance Maintains Huge Position in this Rare Disease Drug Company [content-module:CompanyOverview|NASDAQ:UTHR] At the end of 2024, Renaissance had a stake in United Therapeutics (NASDAQ: UTHR) worth around $737 million. Renaissance's shares held in United Therapeutics first eclipsed 3 million back in Q2 2019. Since then, the stock has provided a total return of around 285% as of the April 29 close. Renaissance has clearly taken gains along the way, with its shares held sitting at around 2.1 million as of Q4 2024. However, since hitting a peak of 3.7 million shares held in Q2 2020, the overall value of the position has increased by around 63%. Today, the company has six medications approved by the Food and Drug Administration. The company's main treatments focus on a rare condition called pulmonary arterial hypertension. Its biggest seller, Tyvaso, generated sales of over $1.6 billion in 2024, growing 31% from 2023. Overall, Renaissance's still large position in United likely stems from a belief that the company will be able to continue growing sales of these treatments at a brisk pace and can continue developing new medicines for rare conditions. Palantir: Meteoric Rise Gives It the Top Spot Despite Renaissance's Big Sale [content-module:CompanyOverview|NASDAQ:PLTR] As of Q4 2024, Renaissance's largest holding is Palantir Technologies (NASDAQ: PLTR), a stock that has done extraordinarily well over the last several years. Since the end of 2022, shares have been up by over 1,700 % as of the close of April 29. Over the course of 2022, Renaissance massively increased its stake in Palantir, growing its number of shares held by over three times. At the end of Q4 2024, the total value of Renaissance's position was over $1.7 billion. However, Renaissance flashed a red flag on Palantir in Q4, reducing its number of shares held by over 40% from Q3 2024. This may not have been the best decision, considering that Palantir stock is up over 200% since the end of Q3. No one knows at what point in Q4 they sold these shares, so Renaissance may have captured a lot of the gain. Still, it's hard to blame the firm for the sale, considering that Palantir trades for a forward price-to-earnings multiple of over 200x. Additionally, Wall Street analysts tracked by MarketBeat see big-time downside potential. What Renaissance's Portfolio Says About Market Trends in 2025 Renaissance's 13F filings offer a rare glimpse into the holdings of a firm widely viewed as the gold standard in hedge fund investing. From long-standing commitments to Novo Nordisk, to strong belief in United Therapeutics, to a cautious trim of the soaring Palantir, the data highlights where one of the sharpest quantitative firms is placing its biggest equity bets. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
Yahoo
11-05-2025
- Business
- Yahoo
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons' Renaissance Technologies?
We recently published a list of In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best stocks to buy according to Jim Simons' Renaissance Technologies. Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the 'Quant King' of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative trading firm based in New York. After years of researching the finance industry, Simons realized the untapped potential of employing quantitative analysis to capitalize on market inefficiencies. This insight led him to develop a data-driven investment strategy of analyzing market behavior solely using statistical and mathematical models. By identifying subtle, non-random patterns in financial data, the quant genius predicted future stock movements and generated impressive returns. Although it is closed to outside investors, Jim Simons' secretive Medallion hedge fund, a flagship of Renaissance, has produced ground-breaking results since its inception. The Medallion Fund raked in impressive returns of 56.6% and 74.6% during the early 2000s dot-com crash and the global financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $31.4 billion, ranking him among the world's wealthiest individuals, thanks to the strong market performance of the Medallion Fund and Renaissance. READ ALSO: and . Renaissance Technologies' computer-driven powerhouse came off to a great start after a stellar performance in 2024. The Renaissance Institutional Diversified Alpha Fund has gained 9.05% as of February, continuing to build on its impressive 2024 return of 15.6%, which was its best since its inception in 2021. Meanwhile, the Renaissance Institutional Equities Fund has had its best start in over ten years, rising 11.85% in the first two months of 2025. Both funds are allowed to maintain sizable individual stock positions in addition to using stock index futures and options to help manage risk. However, the firm warns that it may be difficult to quickly unwind these sizable holdings without impacting market prices. For this list, we picked stocks from Renaissance Technologies' 13F portfolio as of the end of the fourth quarter of 2024. These equities are also popular among elite hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A team of scientists in a laboratory, running tests on a biotechnology product. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and manufactures organ replacements and treatments for organ disorders. The company's three primary medications, Tyvaso, Orenitram, and Remodulin, are targeted at patients, hospitals, and specialty pharmacies. TD Cowen reiterated its Buy rating for United Therapeutics Corporation (NASDAQ:UTHR) on May 7, citing a stable $400 price target. The endorsement follows a recent meeting with the company's management, which took place after their earnings call for the first quarter. TD Cowen analysts stated that management discussed the ongoing introduction of Tyvaso PH-ILD and expressed confidence in the drug's ability to treat Idiopathic Pulmonary Fibrosis (IPF), with preliminary results anticipated in the second half of the year. United Therapeutics Corporation (NASDAQ:UTHR) exceeded market expectations with its first quarter 2025 financial performance. The company reported earnings per share of $6.63, surpassing the projected $6.53, and achieved record revenue of $794.4 million, significantly higher than the expected $728.34 million. Strong demand across its treprostinil product lines, including Tyvaso and Remodulin, contributed to a 17% year-over-year increase in revenue. Overall, UTHR ranks 2nd on our list of best stocks to buy according to Jim Simons' Renaissance Technologies. While we acknowledge the potential for UTHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than UTHR but trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at .
